Watch Again our Webinar on “Percutaneous Implantation of PULSTA Pulmonary Valve. What You Need to Know”.
Self-Expanding Valve in Extreme Surgical Risk After 5 Years
Patients with aortic stenosis and extreme surgical risk have extremely high mortality due to known comorbidities. The short-term benefit of transcatheter aortic valve replacement (TAVR) with self-expanding valve is clear, and it warrants the procedure in this challenging population. While elderly patients with comorbidities who are at extreme surgical risk might be eligible for TAVR,<a href="https://solaci.org/en/2021/06/24/self-expanding-valve-in-extreme-surgical-risk-after-5-years/" title="Read more" >...</a>
EuroPCR 2021 | Evolut Low Risk: Two-Year Results of The Self-Expanding Valve in Low-Risk Patients
Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with low surgical risk. After two years, the primary endpoint of death or disabling stroke was similar between both strategies. This presentation at EuroPCR 2021 reinforces the results presented during the American College of Cardiology (ACC) 2019 Congress and<a href="https://solaci.org/en/2021/05/27/europcr-2021-evolut-low-risk-two-year-results-of-the-self-expanding-valve-in-low-risk-patients/" title="Read more" >...</a>
EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System
The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions. The PASCAL system (Edwards) has been authorized for<a href="https://solaci.org/en/2021/05/26/europcr-2021-clasp-2-year-outcomes-of-the-new-mitral-valve-repair-system/" title="Read more" >...</a>
TAVR vs. the Least Invasive Surgically Implanted Valve
Rapid-deployment surgically implanted valves are designed to make a surgeons’ job faster and easier, compared with conventional bioprostheses, which require several stitches. These valves, which shorten surgical times, could compete with transcatheter-implanted valves (transcatheter aortic valve replacement, TAVR). The German Aortic Valve Registry analyzed 16,473 patients who underwent surgical aortic valve replacement with either a current-generation<a href="https://solaci.org/en/2021/04/19/tavr-vs-the-least-invasive-surgically-implanted-valve/" title="Read more" >...</a>
High Deployment: Also Trending with Balloon Expandable Valves
Conventional implantation of balloon expandable SAPIEN-3 results in a final 70:30 or 80:20 ratio of the valve in the aorta/left ventricular outflow tract. This comes with permanent pacemaker implantation rates of approximately 10%. Higher deployment might translate into lower rates of conduction abnormalities and pacemaker implantation. The study compared a cohort of 1028 consecutive patients; 406<a href="https://solaci.org/en/2021/03/25/high-deployment-also-trending-with-balloon-expandable-valves/" title="Read more" >...</a>
Cusp Overlap for Higher CoreValve Implantation
Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker implantation. Valve implantation 3 to 5 mm below the aortic annulus in a projection coaxial to the device is recommended. The problem is this is rarely in the annular plane of the valve. Ideal annular plane projection is<a href="https://solaci.org/en/2021/03/25/cusp-overlap-for-higher-corevalve-implantation/" title="Read more" >...</a>
Sapien Valve Keeps Delivering in Jobs for Which It Was Not Designed
We recently published the success of balloon-expandable Sapien valve when used as mitral valve replacement. We now hear about its success as pulmonary valve replacement. Previous experiences with this prosthesis for aortic valve replacement have encouraged many operators to attempt fixing other valves. At first, there were exceptional cases considered compassionate treatments. However, experience has<a href="https://solaci.org/en/2020/12/16/sapien-valve-keeps-delivering-in-jobs-for-which-it-was-not-designed/" title="Read more" >...</a>
Boston Scientific Discontinues Lotus Valve and Makes a New Bet
Mechanically-expanding valve Lotus Edge was discontinued worldwide, as recently informed by its manufacturer, Boston Scientific. This is a voluntary recall of all Lotus valve inventory, and the immediate suspension of the program. The United States Food and Drug Administration (FDA) approved Lotus Edge in 2019 for patients with severe aortic stenosis and high surgical risk.<a href="https://solaci.org/en/2020/12/03/boston-scientific-discontinues-lotus-valve-and-makes-a-new-bet/" title="Read more" >...</a>